Neuropeptide Y and gamma-melanocyte stimulating hormone (γ-MSH) share a common pressor mechanism of action

Kenneth Gruber; Wei Fan; Helena Akerberg; Dan Larhammar; Melissa Chee; William Colmers
June 2009
Endocrine (1355008X);Jun2009, Vol. 35 Issue 3, p312
Academic Journal
Abstract  Central circuits known to regulate food intake and energy expenditure also affect central cardiovascular regulation. For example, both the melanocortin and neuropeptide Y (NPY) peptide families, known to regulate food intake, also produce central hypertensive effects. Members of both families share a similar C-terminal amino acid residue sequence, RF(Y) amide, a sequence distinct from that required for melanocortin receptor binding. A recently delineated family of RFamide receptors recognizes both of these C-terminal motifs. We now present evidence that an antagonist with Y1 and RFamide receptor activity, BIBO3304, will attenuate the central cardiovascular effects of both gamma-melanocyte stimulating hormone (γ-MSH) and NPY. The use of synthetic melanocortin and NPY peptide analogs excluded an interaction with melanocortin or Y family receptors. We suggest that the anatomical convergence of NPY and melanocortin neurons on cardiovascular control centers may have pathophysiological implications through a common or similar RFamide receptor(s), much as they converge on other nuclei to coordinately control energy homeostasis.


Related Articles

  • Clinuvel Filing for Scenesse In EU on Phase III Data in EPP. Sheridan, Cormac // BioWorld Today;12/21/2011, Vol. 22 Issue 245, p2 

    The article focuses on a plan by Clinuvel Pharmaceuticals Ltd. to complete a European regulatory filing for its lead drug Scenesse or afamelanotide. Scenesse is indicated for patients with erythropoietic protoporphyria (EPP). Information on the pathogenesis of EPP is provided, along with the...

  • Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain. Kahn, Steven E.; Haffner, Steven M.; Viberti, Giancarlo; Herman, William H.; Lachin, John M.; Kravitz, Barbara G.; Yu, Dahong; Paul, Gitanjali; Holman, Rury R.; Zinman, Bernard // Diabetes Care;Jan2010, Vol. 33 Issue 1, p177 

    OBJECTIVE -- C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; however, the long-term effects of those agents are unknown....

  • C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. Salazar, Juan; Martínez, María Sofía; Chávez-Castillo, Mervin; Núñez, Victoria; Añez, Roberto; Torres, Yaquelin; Toledo, Alexandra; Chacín, Maricarmen; Silva, Carlos; Pacheco, Enrique; Rojas, Joselyn; Bermúdez, Valmore // ISRN Otolaryngology;2014, p1 

    Cardiovascular disease is the leading cause of morbidity and mortality in the adult population worldwide, with atherosclerosis being its key pathophysiologic component. Atherosclerosis possesses a fundamental chronic inflammatory aspect, and the involvement of numerous inflammatory molecules has...

  • Neuropeptide Y functions as a neuroproliferative factor. Hansel, D.E.; Eipper, B.A.; Ronnett, G.V. // Nature;4/19/2001, Vol. 410 Issue 6831, p940 

    Presents information on a study which identified a role for neuropeptide Y (NPY) in promoting proliferation of postnatal neuronal precursor cells. Information on NPY; How the existence of NPY in the olfactory epithelium was confirmed; Five receptors to which NPY can act.

  • Life without neuropeptide Y. Stephens, Thomas W. // Nature;5/30/1996, Vol. 381 Issue 6581, p377 

    Focuses on the report by J.C Erickson et al in the May 30, 1996 issue of `Nature,' on the results of knocking out one of the most important known players in the regulation of body weight, neuropeptide Y (NPY). Mice experiments conducted; Mechanism of the action of the NPY; Evolution of a...

  • Is C-reactive protein specific for vascular disease in women? Rifai, Nader; Buring, Julie E.; I-Min Lee; Manson, JoAnn E.; Ridker, Paul M.; Lee, I-Min // Annals of Internal Medicine;4/2/2002, Vol. 136 Issue 7, p529 

    Background: C-reactive protein (CRP) predicts risk for future cardiovascular events in asymptomatic individuals. However, because CRP also predicts total mortality, its specificity for vascular disease is uncertain.Objective: To compare the predictive value of CRP for...

  • C-reactive protein risk prediction: low specificity, high sensitivity. Koenig, Wolfgang; Pepys, Mark B. // Annals of Internal Medicine;4/2/2002, Vol. 136 Issue 7, p550 

    Editorial. Compares the predictive value of C-reactive protein level for cancer and cardiovascular disease. Similarity in the baseline characteristics between patients; Increase in the incident of cardiovascular events; Value of the relative risk.

  • Is C-Reactive Protein Specific for Vascular Disease in Women? Rifai, N.; Buring, J.E.; Lee, I.-M.; Manson, J.E.; Ridker, P.M. // Annals of Internal Medicine;4/2/2002, Vol. 136 Issue 7, pI42 

    Examines the relation between C-reactive protein (CRP) and cancer. Factors affecting the levels of CRP; Measurement of CRP levels; Association between higher CRP levels and the development of cardiovascular disease.

  • HEART SMART: A TEST TO TAKE. Kent, Kathleen L. // Town & Country;Apr2005, Vol. 159 Issue 5299, p90 

    Highlights the importance of c-reactive protein in predicting cardiovascular risk.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics